We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MedCap Acquires Rights to Syphilis Test

By Labmedica staff writers
Posted on 06 Dec 2004
The acquisition of the exclusive right to market and distribute a rapid test kit for the detection of syphilis has been announced by MedCap Corp. More...
(Toronto, Canada).

With early detection, syphilis is easily cured through a single dose of penicillin taken as an intramuscular injection. The World Health Organization (WHO, Geneva, Switzerland) estimates there are 340 million new cases of syphilis and other sexually transmitted diseases (STDs) each year. The largest number of new infections have occurred in South and Southeast Asia, followed by sub-Saharan Africa, Latin America, and the Caribbean islands. Individuals with syphilis have a three-to-five times increase in the risk of transmitting and acquiring an HIV infection when syphilis is present.

MedCap believes there is a virtually untouched market for a rapid diagnostic test kit related to the detection of syphilis that is easy to use, reasonably priced, and very accurate. The company anticipates that the acquisition of this syphilis test kit will result in substantial revenues.



Related Links:
MedCap Corp.

New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.